Phase II Trial of Copper Depletion with Tetrathiomolybdate as an Antiangiogenesis Strategy in Patients with Hormone-Refractory Prostate Cancer

Publisher： Karger

E-ISSN： 1423-0232|71|3-4|168-175

ISSN： 0030-2414

Source： Oncology, Vol.71, Iss.3-4, 2007-07, pp. : 168-175

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

An Open-Label, Noncomparative Phase II Trial to Evaluate the Efficacy and Safety of Docetaxel in Combination with Gefitinib in Patients with Hormone-Refractory Metastatic Prostate Cancer

By  

Oncology Research and Treatment, Vol. 30, Iss. 7, 2007-06 ,pp. : 355-360

Karger

Access to resources Recommend Favorite

Prednisone plus Gefitinib versus Prednisone plus Placebo in the Treatment of Hormone-Refractory Prostate Cancer: A Randomized Phase II Trial

By  

Oncology, Vol. 74, Iss. 3-4, 2008-08 ,pp. : 223-228

Karger

Access to resources Recommend Favorite

Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs. Prednisone alone in Patients with Hormone-Refractory Prostate Cancer

By  

Oncology, Vol. 68, Iss. 1, 2005-04 ,pp. : 2-9

Karger

Access to resources Recommend Favorite

Phase II Study of Repeated Single 24-Hour Infusion of Low-Dose 5-Fluorouracil for Palliation in Symptomatic Hormone-Refractory Prostate Cancer

By  

Urologia Internationalis, Vol. 69, Iss. 4, 2002-11 ,pp. : 273-277

Karger

Access to resources Recommend Favorite

TREATMENT WITH PREDNISOLONE OF HORMONE-REFRACTORY PROSTATE CANCER

By Fuse H.   Nozaki T.   Fujiuchi Y.   Mizuno I.   Nagakawa O.   Okumura A.  

Archives of Andrology, Vol. 52, Iss. 1, 2006-01 ,pp. : 35-38

Informa Healthcare

Access to resources Recommend Favorite